Brian Wiley
YOU?
Author Swipe
View article: Supplementary Figure S10 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Figure S10 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Two-sample Mendelian randomization (MR) analyses of the causal effect of plasma protein levels on myeloid neoplasm (MN) risk in the UKBB (N=381,485).
View article: Supplementary Table S7 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Table S7 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Association between plasma protein levels and individual clonal hematopoiesis (CH) genes with frequency greater than 20 (N=13 genes).
View article: Supplementary Table S9 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Table S9 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Association between plasma protein levels and blood count measurements.
View article: Supplementary Table S2 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Table S2 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Association between protein levels (N=1,463), myeloid neoplasm (MN) risk and clonal hematopoesisis (CH).
View article: Supplementary Figure S2 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Figure S2 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Association between MN and plasma protein levels stratified by MN subtype (MPN vs. MDS/AML).
View article: Supplementary Table S10 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Table S10 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Asociation between polygenic risk score and risk of myeloid neoplasm (MN) with and without adjusting for CH.
View article: Supplementary Table S6 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Table S6 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Association between plasma protein levels and clonal hematopoiesis (CH) stratified by VAF.
View article: Supplementary Figure S4 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Figure S4 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Association between plasma proteins and common CH genes.
View article: Supplementary Figure S7 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Figure S7 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Prediction of MN risk using clinical, CH, and proteomics data.
View article: Supplementary Figure S1 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Figure S1 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Association between myeloid neoplasm and plasma protein levels stratified by disease subtype.
View article: Supplementary Table S9 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Table S9 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Association between plasma protein levels and blood count measurements.
View article: Supplementary Table S3 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Table S3 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Significantly enriched Reactome gene sets after multiple hypothesis testing correction (pFDR <= 0.05).
View article: Supplementary Figure S4 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Figure S4 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Association between plasma proteins and common CH genes.
View article: Supplementary Table S1 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Table S1 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
List of genes with known relevance to hematologic cancer.
View article: Supplementary Figure S7 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Figure S7 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Prediction of MN risk using clinical, CH, and proteomics data.
View article: Supplementary Figure S10 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Figure S10 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Two-sample Mendelian randomization (MR) analyses of the causal effect of plasma protein levels on myeloid neoplasm (MN) risk in the UKBB (N=381,485).
View article: Supplementary Methods S1 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Methods S1 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Supplementary Methods
View article: Supplementary Table S2 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Table S2 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Association between protein levels (N=1,463), myeloid neoplasm (MN) risk and clonal hematopoesisis (CH).
View article: Supplementary Table S11 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Table S11 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Two-sample Mendelian randomization analyses of the causal effect of plasma protein levels on myeloid neoplasm (MN) risk in the UKBB.
View article: Supplementary Figure S9 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Figure S9 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Discrimination of MN risk integrating Clonal Hematopoiesis Risk Score (CHRS) and proteomics.
View article: Supplementary Table S5 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Table S5 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Association between plasma protein levels and risk of myeloid neoplasm (MN) with and without adjustment for clonal hematopoiesis (CH).
View article: Supplementary Figure S1 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Figure S1 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Association between myeloid neoplasm and plasma protein levels stratified by disease subtype.
View article: Supplementary Figure S8 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Figure S8 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Discrimination of MN risk using reduced set of proteomics features.
View article: Supplementary Table S11 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Table S11 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Two-sample Mendelian randomization analyses of the causal effect of plasma protein levels on myeloid neoplasm (MN) risk in the UKBB.
View article: Supplementary Table S3 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Table S3 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Significantly enriched Reactome gene sets after multiple hypothesis testing correction (pFDR <= 0.05).
View article: Supplementary Table S8 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Table S8 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Association between plasma protein levels and biologically informed categories of clonal hematopoiesis (CH) genes.
View article: Supplementary Figure S5 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Figure S5 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Association between plasma proteins and CH genes with or without blood count correction.
View article: Supplementary Figure S6 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Figure S6 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Association between plasma protein levels and blood count parameters.
View article: Supplementary Table S10 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Table S10 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Asociation between polygenic risk score and risk of myeloid neoplasm (MN) with and without adjusting for CH.
View article: Supplementary Figure S6 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Supplementary Figure S6 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk Open
Association between plasma protein levels and blood count parameters.